Masanori Okaniwa
Research Subjects
Masanori Okaniwa has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Atsushi Matsuda
10 shared publications- Adnan O. Abu-Yousif
Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
9 shared publications Chris Gemski
9 shared publicationsChristopher Arendt
9 shared publicationsDoanh Mai
9 shared publicationsElizabeth Carideo Cunniff
9 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods SM1 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary methods and results: The supplementary methods describe: 1) the chemical synthesis and characterization of TAK-676, inclusive of TAK-676 chemical structure, purification chromatogram and NMR characterization; 2) details regarding STING DNA cloning and purification (recombinant E. coli expression utilizing an N-terminal His tag and C-terminal Avi tag) for STING binding assays (time-resolved fluorescence resonance energy transfer assay); 3) description of pathway activation assays (inclusive of cell culture methods) in THP1-Dualâ„¢, CT26.WT, HEK293T (lack endogenous STING expression), and RAW-Luciaâ„¢ ISG cell lines; 4) methods describing the generation of STING knockout and WT cell line clones in CT26.WT and BF1610 cells via the CRISPR method; 5) details of immune cell activation assays in human dendritic cells, mouse dendritic cells, NK cells and T cells analyzed by flow cytometry; 6) details regarding inoculation of BALB/C mice with A20 cells (for generation of A20 syngeneic tumors) for pharmacokinetic analysis of TAK-676 administered intravenously; 7) details regarding inoculation of BALB/C (and Goldenticket mice with BF1610 tumor cells only) mice with CT26.WT, A20, and B16F10 tumor cells for in vivo antitumor activity analysis; 8) methods describing the in vivo pharmacodynamic effects of TAK-676 by cytokine induction and immune cell activation and proliferation. The supplementary results show that TAK-676 is tolerated in syngeneic mouse models supported by Supplementary Figure 3 (percentage body weight change in BALB/C mice [CT26.WT and A20 syngeneic tumors]) and Supplementary Figure 4 (percentage body weight change in STING-deficient Goldenticket mice [STING WT and B16F10 syngeneic tumors]).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods SM1 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary methods and results: The supplementary methods describe: 1) the chemical synthesis and characterization of TAK-676, inclusive of TAK-676 chemical structure, purification chromatogram and NMR characterization; 2) details regarding STING DNA cloning and purification (recombinant E. coli expression utilizing an N-terminal His tag and C-terminal Avi tag) for STING binding assays (time-resolved fluorescence resonance energy transfer assay); 3) description of pathway activation assays (inclusive of cell culture methods) in THP1-Dualâ„¢, CT26.WT, HEK293T (lack endogenous STING expression), and RAW-Luciaâ„¢ ISG cell lines; 4) methods describing the generation of STING knockout and WT cell line clones in CT26.WT and BF1610 cells via the CRISPR method; 5) details of immune cell activation assays in human dendritic cells, mouse dendritic cells, NK cells and T cells analyzed by flow cytometry; 6) details regarding inoculation of BALB/C mice with A20 cells (for generation of A20 syngeneic tumors) for pharmacokinetic analysis of TAK-676 administered intravenously; 7) details regarding inoculation of BALB/C (and Goldenticket mice with BF1610 tumor cells only) mice with CT26.WT, A20, and B16F10 tumor cells for in vivo antitumor activity analysis; 8) methods describing the in vivo pharmacodynamic effects of TAK-676 by cytokine induction and immune cell activation and proliferation. The supplementary results show that TAK-676 is tolerated in syngeneic mouse models supported by Supplementary Figure 3 (percentage body weight change in BALB/C mice [CT26.WT and A20 syngeneic tumors]) and Supplementary Figure 4 (percentage body weight change in STING-deficient Goldenticket mice [STING WT and B16F10 syngeneic tumors]).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary figures: Supplementary Figure 1 shows cell viability of human monocyte-derived dendric cells and mouse bone marrow dendritic cells. Supplementary Figure 2 shows mean plasma and tumor concentration-time curves of TAK-676 in BALB/C mice (A20 syngeneic tumors). Supplementary Figure 3 shows percentage body weight change in BALB/C mice (CT26.WT and A20 syngeneic tumors). Supplementary Figure 4 shows percentage body weight change in STING-deficient Goldenticket mice (STING WT and B16F10 syngeneic tumors). Supplementary Figure 5 shows cytokine expression in A20 tumor-bearing mice (plasma and tumor).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary figures: Supplementary Figure 1 shows cell viability of human monocyte-derived dendric cells and mouse bone marrow dendritic cells. Supplementary Figure 2 shows mean plasma and tumor concentration-time curves of TAK-676 in BALB/C mice (A20 syngeneic tumors). Supplementary Figure 3 shows percentage body weight change in BALB/C mice (CT26.WT and A20 syngeneic tumors). Supplementary Figure 4 shows percentage body weight change in STING-deficient Goldenticket mice (STING WT and B16F10 syngeneic tumors). Supplementary Figure 5 shows cytokine expression in A20 tumor-bearing mice (plasma and tumor).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary tables: Supplementary Table 1 describes where cells were obtained from and details of authentication and mycoplasma testing dates. Supplementary Table 2 shows TAK-676 potency in cynomolgus monkey, human, mouse, and rat STING via time-resolved fluorescence resonance energy transfer assay. Supplementary Table 3 shows pharmacokinetic parameters (Cmax and AUC) after TAK-676 administration in BALB/C mice (A20 tumors).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary tables: Supplementary Table 1 describes where cells were obtained from and details of authentication and mycoplasma testing dates. Supplementary Table 2 shows TAK-676 potency in cynomolgus monkey, human, mouse, and rat STING via time-resolved fluorescence resonance energy transfer assay. Supplementary Table 3 shows pharmacokinetic parameters (Cmax and AUC) after TAK-676 administration in BALB/C mice (A20 tumors).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods SM1 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary methods and results: The supplementary methods describe: 1) the chemical synthesis and characterization of TAK-676, inclusive of TAK-676 chemical structure, purification chromatogram and NMR characterization; 2) details regarding STING DNA cloning and purification (recombinant E. coli expression utilizing an N-terminal His tag and C-terminal Avi tag) for STING binding assays (time-resolved fluorescence resonance energy transfer assay); 3) description of pathway activation assays (inclusive of cell culture methods) in THP1-Dualâ„¢, CT26.WT, HEK293T (lack endogenous STING expression), and RAW-Luciaâ„¢ ISG cell lines; 4) methods describing the generation of STING knockout and WT cell line clones in CT26.WT and BF1610 cells via the CRISPR method; 5) details of immune cell activation assays in human dendritic cells, mouse dendritic cells, NK cells and T cells analyzed by flow cytometry; 6) details regarding inoculation of BALB/C mice with A20 cells (for generation of A20 syngeneic tumors) for pharmacokinetic analysis of TAK-676 administered intravenously; 7) details regarding inoculation of BALB/C (and Goldenticket mice with BF1610 tumor cells only) mice with CT26.WT, A20, and B16F10 tumor cells for in vivo antitumor activity analysis; 8) methods describing the in vivo pharmacodynamic effects of TAK-676 by cytokine induction and immune cell activation and proliferation. The supplementary results show that TAK-676 is tolerated in syngeneic mouse models supported by Supplementary Figure 3 (percentage body weight change in BALB/C mice [CT26.WT and A20 syngeneic tumors]) and Supplementary Figure 4 (percentage body weight change in STING-deficient Goldenticket mice [STING WT and B16F10 syngeneic tumors]).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods SM1 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary methods and results: The supplementary methods describe: 1) the chemical synthesis and characterization of TAK-676, inclusive of TAK-676 chemical structure, purification chromatogram and NMR characterization; 2) details regarding STING DNA cloning and purification (recombinant E. coli expression utilizing an N-terminal His tag and C-terminal Avi tag) for STING binding assays (time-resolved fluorescence resonance energy transfer assay); 3) description of pathway activation assays (inclusive of cell culture methods) in THP1-Dualâ„¢, CT26.WT, HEK293T (lack endogenous STING expression), and RAW-Luciaâ„¢ ISG cell lines; 4) methods describing the generation of STING knockout and WT cell line clones in CT26.WT and BF1610 cells via the CRISPR method; 5) details of immune cell activation assays in human dendritic cells, mouse dendritic cells, NK cells and T cells analyzed by flow cytometry; 6) details regarding inoculation of BALB/C mice with A20 cells (for generation of A20 syngeneic tumors) for pharmacokinetic analysis of TAK-676 administered intravenously; 7) details regarding inoculation of BALB/C (and Goldenticket mice with BF1610 tumor cells only) mice with CT26.WT, A20, and B16F10 tumor cells for in vivo antitumor activity analysis; 8) methods describing the in vivo pharmacodynamic effects of TAK-676 by cytokine induction and immune cell activation and proliferation. The supplementary results show that TAK-676 is tolerated in syngeneic mouse models supported by Supplementary Figure 3 (percentage body weight change in BALB/C mice [CT26.WT and A20 syngeneic tumors]) and Supplementary Figure 4 (percentage body weight change in STING-deficient Goldenticket mice [STING WT and B16F10 syngeneic tumors]).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance:TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance:TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary tables: Supplementary Table 1 describes where cells were obtained from and details of authentication and mycoplasma testing dates. Supplementary Table 2 shows TAK-676 potency in cynomolgus monkey, human, mouse, and rat STING via time-resolved fluorescence resonance energy transfer assay. Supplementary Table 3 shows pharmacokinetic parameters (Cmax and AUC) after TAK-676 administration in BALB/C mice (A20 tumors).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary tables: Supplementary Table 1 describes where cells were obtained from and details of authentication and mycoplasma testing dates. Supplementary Table 2 shows TAK-676 potency in cynomolgus monkey, human, mouse, and rat STING via time-resolved fluorescence resonance energy transfer assay. Supplementary Table 3 shows pharmacokinetic parameters (Cmax and AUC) after TAK-676 administration in BALB/C mice (A20 tumors).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary figures: Supplementary Figure 1 shows cell viability of human monocyte-derived dendric cells and mouse bone marrow dendritic cells. Supplementary Figure 2 shows mean plasma and tumor concentration-time curves of TAK-676 in BALB/C mice (A20 syngeneic tumors). Supplementary Figure 3 shows percentage body weight change in BALB/C mice (CT26.WT and A20 syngeneic tumors). Supplementary Figure 4 shows percentage body weight change in STING-deficient Goldenticket mice (STING WT and B16F10 syngeneic tumors). Supplementary Figure 5 shows cytokine expression in A20 tumor-bearing mice (plasma and tumor).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Supplementary figures: Supplementary Figure 1 shows cell viability of human monocyte-derived dendric cells and mouse bone marrow dendritic cells. Supplementary Figure 2 shows mean plasma and tumor concentration-time curves of TAK-676 in BALB/C mice (A20 syngeneic tumors). Supplementary Figure 3 shows percentage body weight change in BALB/C mice (CT26.WT and A20 syngeneic tumors). Supplementary Figure 4 shows percentage body weight change in STING-deficient Goldenticket mice (STING WT and B16F10 syngeneic tumors). Supplementary Figure 5 shows cytokine expression in A20 tumor-bearing mice (plasma and tumor).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance:TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance:TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- Open Access
- 23 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 2  (6) , 489-502
TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance: TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- 23 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 2  (6) , 489-502
Open AccessTAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.Significance: TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
- Top Cited PapersOpen Access
- 23 May 2022
- Published by Springer Nature in Nature Materials
- Vol. 21  (6) , 710-720
STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
Activation of the innate immune STimulator of INterferon Genes (STING) pathway potentiates antitumour immunity, but systemic delivery of STING agonists to tumours is challenging. We conjugated STING-activating cyclic dinucleotides (CDNs) to PEGylated lipids (CDN-PEG-lipids; PEG, polyethylene glycol) via a cleavable linker and incorporated them into lipid nanodiscs (LNDs), which are discoid nanoparticles formed by self-assembly. Compared to state-of-the-art liposomes, intravenously administered LNDs carrying CDN-PEG-lipid (LND-CDNs) exhibited more efficient penetration of tumours, exposing the majority of tumour cells to STING agonist. A single dose of LND-CDNs induced rejection of established tumours, coincident with immune memory against tumour rechallenge. Although CDNs were not directly tumoricidal, LND-CDN uptake by cancer cells correlated with robust T-cell activation by promoting CDN and tumour antigen co-localization in dendritic cells. LNDs thus appear promising as a vehicle for robust delivery of compounds throughout solid tumours, which can be exploited for enhanced immunotherapy.
- 23 May 2022
- Published by Springer Nature in Nature Materials
- Vol. 21  (6) , 710-720
Top Cited PapersOpen AccessSTING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
Activation of the innate immune STimulator of INterferon Genes (STING) pathway potentiates antitumour immunity, but systemic delivery of STING agonists to tumours is challenging. We conjugated STING-activating cyclic dinucleotides (CDNs) to PEGylated lipids (CDN-PEG-lipids; PEG, polyethylene glycol) via a cleavable linker and incorporated them into lipid nanodiscs (LNDs), which are discoid nanoparticles formed by self-assembly. Compared to state-of-the-art liposomes, intravenously administered LNDs carrying CDN-PEG-lipid (LND-CDNs) exhibited more efficient penetration of tumours, exposing the majority of tumour cells to STING agonist. A single dose of LND-CDNs induced rejection of established tumours, coincident with immune memory against tumour rechallenge. Although CDNs were not directly tumoricidal, LND-CDN uptake by cancer cells correlated with robust T-cell activation by promoting CDN and tumour antigen co-localization in dendritic cells. LNDs thus appear promising as a vehicle for robust delivery of compounds throughout solid tumours, which can be exploited for enhanced immunotherapy.